Maviret (Glecaprevir, Pibrentasvir)

Glecaprevir blocks the HCV NS3/4A protease, preventing cleavage of the viral polyprotein, while pibrentasvir binds to the NS5A protein, disrupting the formation of the replication complex. Together they halt viral replication, allowing the immune system to clear infected cells.

The prescribed dose of Maviret is determined by the treating physician based on the patient’s genotype, liver status and prior treatment history. Typically the tablet containing 100 mg glecaprevir and 40 mg pibrentasvir is taken once daily with food, but exact dosing must follow the clinician’s order.

Safety data for glecaprevir/pibrentasvir in pregnancy and lactation are limited. The drug is not recommended for use in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant. Clinicians should discuss alternatives and risk‑benefit considerations with patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Maviret. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other direct‑acting antiviral regimens, Maviret offers a pan‑genotypic option that can be used in a single daily tablet, simplifying therapy. It is effective in patients with compensated cirrhosis and has a relatively short treatment duration, but selection depends on individual patient factors, resistance profiles and potential drug interactions.

Maviret tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Maviret is taken orally as a single tablet containing 100 mg glecaprevir and 40 mg pibrentasvir. The tablet should be swallowed whole with a meal to enhance absorption. Patients should follow the dosing schedule prescribed by their healthcare provider and complete the full course of therapy.

Serious adverse events, although uncommon, can include significant elevations in liver enzymes, hepatic decompensation, severe rash or allergic reactions, and rare cases of anemia or renal impairment. Patients should be monitored regularly for signs of liver dysfunction and any severe or unexpected symptoms should prompt immediate medical evaluation.

Maviret is contraindicated in patients receiving strong CYP3A inducers such as rifampin, carbamazepine or St. John’s wort, as these can markedly reduce drug exposure. It should also be avoided in individuals with severe hepatic impairment (Child‑Pugh class B or C) and in those with known hypersensitivity to glecaprevir, pibrentasvir or any tablet components.